U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down
Related Posts
Add A Comment